Our pipeline

LNC Therapeutics
programs & projects

Our strategy:

Stablor®  program

Building on the promising results of OBEMINALE 1, a confirmatory study – dubbed OBEMINALE 2 – was launched in 2018, aimed at obtaining an EFSA 13(5) health claim for Stablor® in 2020 and then licensing-out the product to a commercial partner


Bring the first drug based on the Christensenella minuta gut bacteria targeting obesity and metabolic disorders into the first clinical trial planned for 2020


Unlock the potential of the Christensenellaceae family of bacteria via our dedicated platform, in order to identify new therapeutic applications


Incubate and maturate microbiome-related exploratory projects likely to become new drug candidates to expand our pipeline

Microbiome & us
Jan 13, 2020
We are looking for Clinical Project Manager | WHAT WE OFFER An exciting opportunity to dive in and begin your career...
> more
Dec 11, 2019
LNC Therapeutics and the National Institute for Agricultural Research (INRA) sign research partnership to study anti-...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
Oct 28, 2019
Jillian L. Waters, Ruth E. Ley The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging...
> more
now on twitter
LNC Therapeutics

Eating right for gut health – An interview with Natasha Haskey, Registered Dietitian. Via @GutMicrobiotaWWt.co/NvixosaooE

LNC Therapeutics © 2020 - all rights reserved terms and conditions